PGS Sample Set (PSS): PSS001070

Phenotype All individuals had non-small cell lung cancer (NSCLC) and were receiving immune checkpoint inhibitor (CPI) therapy. of the 744 individuals receiving CPI therapy, 659 were being treated with Anti-PD-(L)1 monotherapy whilst 85 were being treated with Anti-PD-(L)1+CTLA-4 combination therapy. Cases were individuals who had experienced immune-related thyroid dysfunction following CPI therapy. A thyroid event after the start of CPI therapy was defined as either (1) incident hypothyroidism or (2) transient incident hyperthyroidism followed by incident hypothyroidism. Incident hypothyroidism was defined as (a) a TSH of ≥ 10 mU/L or (b) TSH of ≥ 5 mU/L with a new prescription of levothyroxine ≥ 50 mcg. Incident hyperthyroidism was defined as TSH < 0.05 mU/L.
Sample Ancestry European, African unspecified, Asian unspecified, Hispanic or Latin American, NR
Additional Ancestry Description European = 634, African unspecified = 50, Asian unspecified = 36, Not reported = 4, Hispanic or Latin American = 20

Sample Numbers

Total number
744 individuals
Detailed numbers
95 cases (12.77%)
649 controls
50.94% Male samples
Number of Cohort(s) 1
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
MSKCC Memorial Sloan Kettering Cancer Center

Additional information

Additional cases and controls were obtained from the Vanderbilt University Medical Centre (VUMC)